Ieq Capital LLC Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Ieq Capital LLC purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 227,421 shares of the biotechnology company’s stock, valued at approximately $2,274,000. Ieq Capital LLC owned 0.09% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Larson Financial Group LLC raised its position in BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,267 shares during the last quarter. Allworth Financial LP purchased a new stake in shares of BioCryst Pharmaceuticals in the second quarter valued at about $52,000. Pallas Capital Advisors LLC acquired a new position in shares of BioCryst Pharmaceuticals during the second quarter worth about $101,000. Focus Partners Wealth acquired a new position in shares of BioCryst Pharmaceuticals during the third quarter worth about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Wedbush reduced their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Royal Bank Of Canada dropped their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. initiated coverage on BioCryst Pharmaceuticals in a research note on Monday, July 13th. They set a “neutral” rating and a $12.00 target price for the company. Citizens Jmp raised their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Finally, Cantor Fitzgerald lifted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $9.83 on Wednesday. The company has a market cap of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.56. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22. The business’s fifty day moving average is $9.66 and its two-hundred day moving average is $9.00.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business’s revenue was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.15 EPS. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.